🔎 Trials Near Me

Beranda › Kanker Bronkus › Texas

Uji klinis Kanker Bronkus di Texas

5 studi untuk Kanker Bronkus mencari peserta di lokasi di Texas.

Kota di Texas

Teks studi resmi (Bahasa Inggris)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • MD Anderson, Houston
  • NEXT Dallas, Irving
  • NEXT Oncology San Antonio, San Antonio
  • dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Texas Oncology, Austin
  • William Beaumont Army Medical Center, Fort Bliss
  • Houston Methodist Hospital, Houston
  • dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • Texas Oncology, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07185997

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • UT Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT02984761

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.